Afimkibart not checked
Roche · PF-06480605 · Cohorts 1 and 2 Active
FollowEvery change as it happens, and a Monday email
Trials
14 active
19 in total · 10 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
- How it’s given
- “Participants will receive afimkibart IV followed by afimkibart subcutaneous SC injection.”In the company’s words, NCT06588855 on ClinicalTrials.gov
- Tested for
- Moderately to Severely Active Ulcerative Colitis (4 trials), Moderately to Severely Active Crohns Disease (3 trials), Atopic Dermatitis (2 trials), Rheumatoid Arthritis (2 trials), Crohns Disease, MASH, Active Ulcerative Colitis
- Main trialPhase 3
- “This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).”In the company’s words, NCT06588855 on ClinicalTrials.gov
- Other names
- PF-06480605 · Cohorts 1 and 2 Active · RO7790121 · RVT-3101 · RG6631
Other drugs for Moderately to Severely Active Ulcerative Colitis
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- ObefazimodAbivax S.A. · Phase 3
Coming up11
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
- 30 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 17 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 Jul 2027Phase 1 trial completes · ClinicalTrials.gov
- 31 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 31 Mar 2030Phase 3 trial completes · ClinicalTrials.gov
- 31 May 2030Phase 3 trial completes · ClinicalTrials.gov
- 1 Mar 2033Phase 2 trial completes · ClinicalTrials.gov
- 8 Jul 2033Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials19
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 29 Oct 2026 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 3Active, not recruiting | 30 Jan 2027 | A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 3Recruiting | 31 May 2028 | A Study to Assess the Efficacy and Safety of Subcutaneous Induction Therapy With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 3Recruiting | 31 Dec 2028 | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 3Recruiting | 31 Dec 2028 | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 3Recruiting | 31 Mar 2030 | A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis | |
| Phase 3Recruiting | 31 May 2030 | A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease | |
| Phase 2Active, not recruiting | 22 Jul 2026 | A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis | |
| Phase 2Active, not recruiting | 31 Dec 2026 | Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease | |
| Phase 2Recruiting | 17 Apr 2027 | A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | |
| Phase 2Active, not recruiting | 1 Mar 2033 | A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis | |
| Phase 2Recruiting | 8 Jul 2033 | An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis | |
| Phase 1Active, not recruiting | 24 Sep 2026 | A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis | |
| Phase 1Recruiting | 31 Jul 2027 | An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis | |
| Phase 2Completed | 31 May 2018 | Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. | |
| Phase 2Completed | 25 Oct 2022 | A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis | |
| Phase 2Withdrawn | 15 Aug 2026 | Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease | |
| Phase 1Completed | Mar 2015 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects. | |
| Phase 1Completed | 11 Nov 2020 | Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026